Kepivance market forecast points to steady growth through 2035

The Business Research Company says the global Kepivance market is set to expand through 2035 as cancer treatment volumes rise, stem cell transplants increase and supportive oncology care gains priority. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Kepivance is used to reduce oral mucositis, a painful side effect of chemotherapy and stem cell transplantation that can disrupt cancer care. - The market outlook signals growing demand for supportive oncology drugs as more patients undergo intensive cancer treatment. - Rising use of personalized medicine and hospital-based supportive care could widen the role of palifermin in treatment protocols.

What happened: - The Business Research Company published a Kepivance market forecast covering 2026-2035. - The report says the Kepivance market is gaining attention as cancer treatments and supportive care evolve. - The report also says North America held the largest market share in 2025. - The Asia-Pacific region is projected to be the fastest-growing market going forward. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the report. - View the full report.

The details: - Kepivance, or palifermin, is a recombinant human keratinocyte growth factor designed to stimulate epithelial cell proliferation. - The drug is used to lessen the frequency and severity of oral mucositis in patients receiving myelotoxic cancer therapies, including hematopoietic stem cell transplantation. - The report cites historical market growth tied to high oral mucositis rates during chemotherapy, limited prevention options, more bone marrow transplants, clinical validation of KGF therapy and hospital adoption of supportive care medications. - The report expects future growth from higher cancer treatment volumes, more hematopoietic stem cell transplants, stronger focus on quality of life, larger supportive oncology budgets and progress in epithelial-regeneration therapies. - Key trends identified for the coming years include more emphasis on supportive oncology care, growth in stem cell transplant procedures, better management of treatment-induced mucositis, preference for preventive therapies and integration of growth factors into oncology protocols. - Cancer incidence is a major driver for demand. The American Cancer Society reported in January 2024 that U.S. cancer cases rose to 2,001,140 from 1,958,310 in 2023, a 2.19% increase. - Healthcare infrastructure expansion is another growth factor because specialized facilities and trained personnel support intravenous administration and patient monitoring. - Sports Medical reported in January 2025 that hospitals accounted for 41% of health project starts in the UK in 2024, valued at $2.61 billion (£2 billion), up 9% year over year. - Sports Medical also reported that nursing homes accounted for 17% of UK health project starts in 2024, valued at $1.07 billion (£822 million), up 25%. - The report says personalized medicine is boosting demand because individualized treatment plans can optimize Kepivance use for patients at high risk of oral mucositis. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies in 2023, up from six in 2022. - Those approvals included seven cancer drugs and treatments for other rare diseases.

Between the lines: - The forecast frames Kepivance as part of a broader shift in oncology toward supportive care, not just tumor treatment. - Market growth appears tied less to a single breakthrough and more to several tailwinds moving together: more cancer cases, more transplant procedures and more hospital capacity. - North America's lead suggests established reimbursement, oncology infrastructure and transplant access still matter most for adoption. - Asia-Pacific's projected growth points to rising demand in markets that are still expanding access to advanced cancer care.

What's next: - The report points to continued market expansion through 2035 if cancer treatment volumes and transplant activity keep rising. - Broader adoption may depend on how quickly supportive oncology budgets and hospital infrastructure grow. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated trend analysis. - For more information, contact the company.